Introgen Therapeutics Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Introgen Therapeutics

INGN 6.865

+4.2%

Nov 21 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: DewDiligence_on_SI who wrote (626)	2/15/2007 12:59:00 AM
From: Jibacoa	Read Replies (1) of 802

I thought AF’s write-up was pretty good Which points did he raise ? He stated "There's nothing wrong with data-mining, per se, except when you do it to spin a negative trial into a positive one. That's when retrospective data analysis becomes misleading and wrong, which is what Introgen has done with Advexin." Then he gives an example of "drug X" having an statistically significant result on left handed patients receiving drug X for lung cancer. ADVEXIN therapy combines the p53 tumor suppressor gene with a non-replicating, non-integrating adenoviral gene delivery system and the fact that the "data-mining" or "data analysis",(to which he admits there is "nothing wrong with")showed a highly significant correlation of abnormal p53 protein levels with increased survival of patients treated with ADVEXIN and that recurrent head and neck cancer patients with the abnormal p53 biomarker were most likely to have a survival benefit from ADVEXIN p53 therapy and were the least likely to benefit from conventional treatment.(Median survival of patients with tumors abnormally expressing p53 was 11.6 months compared to only 3.5 months in patients whose tumors did not have the p53 biomarker.)That seems to be significant information obtained from the "data-mining".<g> He said that what Introgen did was misleading and wrong It seems that what is misleading and wrong is the example of "data-mining" he gives of "drug X" with left handed patients , which has no possible correlation whatsoever and is just a baseless and sneering comparison. He doesn't mention that the European Medicines Evaluation Agency has granted the Orphan Medicinal Product Designation in Europe for the treatment of Li-Fraumeni SyndromFS using ADVEXIN He doesn't mention that the FDA designated Fast Track Drug Product Development program and Orphan Drug status for ADVEXIN® in head and neck cancer. He doesn't mention recent studies showing synergistic activity resulting in a curative therapeutic effect in the treatment of lung cancer following the combination of Avastin with INGN 241. In contrast, treatment with Avastin alone demonstrated only minor tumor regression and no cures.(This study was conducted at The University of Texas M.D. Anderson Cancer.) He doesn't mention any other INGN's products. I don't know AF and don't know what is his scientific or biotechnology background if any. He apparently works for The Street.com and I don't know if he is another clown like J.Cramer,but I just don't pay any attention to them. Bernard

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next